Navigation Links
Orexigen and Takeda Announce Multiple Contrave Data Presentations at the ObesityWeek Meeting in Atlanta
Date:11/11/2013

temprop="name">Susan McElroy, MD; Research Institute, Lindner Center of HOPE, Mason, OH, USA.
Title: Naltrexone/bupropion is associated with early and longer-term improvement in binge eating disorder that is related to improvement in depression

About Contrave
About Contrave (32 mg naltrexone sustained‐release (SR)/360 mg bupropion SR) being evaluated for the treatment of obesity: In 2012, Orexigen enrolled more than 10,400 with approximately 8900 randomized patients in the Light Study. The primary objective of the double‐blind, randomized, placebo‐controlled Light Study, which Orexigen is conducting under a Special Protocol Assessment with the U.S. Food and Drug Administration (FDA), is to assess the occurrence of major adverse cardiovascular events in overweight and obese patients receiving Contrave. An interim analysis of the Light Study is anticipated by early December, enabling the potential resubmission of the Contrave New Drug Application to the FDA by year end.

In October, Orexigen submitted a Marketing Authorization Application for Contrave to the European Medicines Agency.

Orexigen has licensed North American Contrave commercial rights to Takeda Pharmaceuticals. Orexigen owns Contrave rights in Europe and throughout the rest of the world outside of North America and will seek a partner to commercialize Contrave in those territories.

About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The company's lead product candidate is Contrave, which has completed Phase 3 clinical trials and for which a NDA has been submitted and reviewed by the FDA. The company has also reached agreement with the FDA on a SPA for the Light Study, the Contrave cardiovascular outcomes trial. The company's other product candidate, Empatic, has completed Phase 2 clinical t
'/>"/>

SOURCE Orexigen Therapeutics, Inc.; Takeda Pharmaceuticals, U.S.A., Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
2. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
3. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
4. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
5. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
6. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
7. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
8. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
9. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
10. Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
11. Orexigen Therapeutics to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... ZIONA, Israel , June 29, ... BVXV, TASE: BVXV) today announced positive preliminary results from ... candidate for a universal influenza vaccine. In this trial, ... of 50 to 65, followed by an administration of ... later. M-001 was found to be safe and well ...
(Date:6/29/2015)... Calif. , June 29, 2015  Isis Pharmaceuticals, ... has been added to the Russell 1000 Index, effective ... performance of the large-cap segment of the U.S. equity ... Index and includes approximately 1000 of the largest securities ... current index membership. "We are pleased to ...
(Date:6/29/2015)... Calif. , June 29, 2015  Arbor ... medical workstation lineup. The high-powered, multi-functional M2150 ... generation Intel® Haswell Core i5-4402E 1.6 ... provide significant data processing and computing performance. Integrated ... making the unit well suited for graphics-intense applications ...
Breaking Medicine Technology:BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 2BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 3ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 2ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 3Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 2Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 3
... , CHEYENNE, Wyo., Aug. 24 The ... of its Pay-for-Participation (P4P) program, a component of its innovative ... collaboration between the practitioner community and the Wyoming EqualityCare (EC) ... Wyoming Medicaid members. , , (Logo: ...
... Curemark Founder and CEO Dr. Joan Fallon delivered the ... Conference at Harvard Medical School on July 14th. , ... conclave is particularly significant, since epigenetics is the study of ... in the DNA sequence. Presenters at the session showcased many ...
Cached Medicine Technology:Wyoming Department of Health's Pay-for-Participation Program Reports Positive Clinical Outcomes 2Wyoming Department of Health's Pay-for-Participation Program Reports Positive Clinical Outcomes 3Curemark CEO Presents at Epigenomics Conference 2
(Date:6/29/2015)... ... June 29, 2015 , ... New research ... fewer than 10 percent of U.S. state and local governments have implemented Next ... implementation deadline for NG9-1-1. , “Mobile phones have surpassed land lines as ...
(Date:6/29/2015)... ... 2015 , ... The Food Safety and Technology Research Centre ... Polytechnic University (PolyU) has developed a new method for rapid authentication of edible ... long-term issue in food safety, and becomes particularly important with the emergence and ...
(Date:6/29/2015)... ... June 29, 2015 , ... FACE is proud to be one of the ... of the double chin and redefining of the jawline. Excess fat under the ... and heavier causing the person distress and poor self-image. , Kybella was produced by ...
(Date:6/29/2015)... ... 29, 2015 , ... DISC, a method of behavioral analysis ... for corporate training seminars. As many as seventy percent of Fortune 500 companies ... increase productivity. , With the demand for in-house DISC training continuing to ...
(Date:6/29/2015)... , ... June 29, 2015 , ... Care to Care, ... to Care. , Dr. Faber will lead the Radiation Oncology Services Program, with a ... the use of Care to Care’s proprietary evidence based criteria. He will assist ...
Breaking Medicine News(10 mins):Health News:State and Local Governments Are Slow to Adopt Next Generation 9-1-1 Systems, According to New Research from General Dynamics Information Technology 2Health News:State and Local Governments Are Slow to Adopt Next Generation 9-1-1 Systems, According to New Research from General Dynamics Information Technology 3Health News:State and Local Governments Are Slow to Adopt Next Generation 9-1-1 Systems, According to New Research from General Dynamics Information Technology 4Health News:PolyU develops a new method for rapid authentication of edible oils and screening of gutter oils 2Health News:FACE Detroit Skin and Wellness Clinic Introduces Newly FDA Approved Kybella for the elimination of the Double Chin. 2Health News:As Demand for DISC Trainers Rises, PeopleKeys Offers Support with “THE DISC FACTOR—Train the Trainer” Webinar 2Health News:Care to Care, LLC Appoints a New Section Chief of Radiation Oncology 2Health News:Care to Care, LLC Appoints a New Section Chief of Radiation Oncology 3
... can be risky, research suggests , , THURSDAY, April 3 (HeathDay News) ... time to have your first child? , Turns out, that,s just ... next baby -- if you decide to have more than one. ... risk of having a baby born premature and with a host ...
... G. Rendell today signed House Bill 874 into law., ... is designed to educate,pregnant women about the potential benefits ... the donation and storage of,umbilical cord blood when they ... committed to creating a first-rate public,education system, protecting our ...
... PITTSBURGH, April 3, 2008 , WHO: GNC, along with figure professionals ... WHAT: The MORE Magazine Health and Wellness Expo ... 12 -7 p.m. April 4, and 11 a.m. to 5 p.m. April 5, 2008 ... Avenues), Come to GNC,s ...
... March of Dimes,Fund-raising Walk Still All About Babies, WHITE ... call it, March of Dimes premier fundraising walk is all,about ... weekend in April in hundreds,of communities nationwide., This year, ... work to help moms and babies -- those born healthy ...
... place again in the,Texas Medical Center as Houston-based LifeGift ... and one of a handful in the nation --,with ... work,in that facility is expected to help save the ... "This building will provide us to the opportunity ...
... 3 /PRNewswire-FirstCall/ - NUCRYST Pharmaceuticals,Corp. (NASDAQ: NCST ; ... down as Vice President Finance & Administration and Chief ... company in a field,unrelated to any of NUCRYST,s businesses, ... for Mr. Lurier,s successor., "On behalf of the ...
Cached Medicine News:Health News:When It Comes to Pregnancy, Timing Is Everything 2Health News:When It Comes to Pregnancy, Timing Is Everything 3Health News:GNC to Run Sweepstakes, Raffle Fitness Equipment at MORE Magazine Health and Wellness Expo 2Health News:March For Babies Has Celebrity Support -- Now It Needs Yours 2Health News:Houston-Based LifeGift Becomes State's Only Stand-Alone Organ and Tissue Recovery Agency 2Health News:NUCRYST Announces Senior Management Change 2Health News:NUCRYST Announces Senior Management Change 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: